

April 23, 2020

SUBSTANTIALLY EQUIVALENT

Philip Morris USA, Inc.
Attention: Rebecca A. Rivas, Senior Director, Regulatory Submissions
Altria Client Services LLC
601 East Jackson Street
Richmond, Virginia 23219

FDA Submission Tracking Numbers (STNs): Multiple STNs, see Appendix A

Dear Ms. Rivas:

We completed our review of your SE Reports¹ and determined that the new tobacco products are substantially equivalent to the corresponding predicate tobacco products listed in Appendix A² and are in compliance with the requirements of the FD&C Act. Under the provisions of section 910 and 905(j) of the FD&C Act, you may introduce or deliver for introduction into interstate commerce the new tobacco products subject of this letter.

Our finding does <u>not</u> mean we "approved" the new products specified in Appendix A; therefore, you may not promote or in any way represent the new tobacco products specified in Appendix A, or the labeling, as being "approved" by FDA (see Section 301(tt) of the FD&C Act).

For information on how to fulfill the provisions of section 910(a)(4) of the FD&C Act, refer to Appendix B.

In accordance with 40 CFR 1506.6, we will make your Environmental Assessment (EA) publicly available.

All regulated tobacco products, including the tobacco products specified in Appendix A, are subject to the requirements of the FD&C Act and its implementing regulations. It is your responsibility to ensure the tobacco products specified in Appendix A complies with all applicable statutory and regulatory requirements. FDA will monitor your compliance with all applicable statutes and regulations.

¹ Substantially Equivalent (SE) Reports submitted under section 905(j) of the Federal Food, Drug, and Cosmetic Act (FD&C Act)

² In addition to comparing the new tobacco products to the predicate tobacco product named by the applicant, FDA also compared the new tobacco product in SE0015426, this SE Report, to the grandfathered tobacco product in SE0014849. Although the new product have different characteristics than the grandfathered tobacco product in SE0014849, FDA found that those differences do not cause the new tobacco product to raise different questions of public health, and thus the new tobacco product is also substantially equivalent to the grandfathered product in SE0014849.

If you have any questions, please contact Pin Zhang, Ph.D., Regulatory Health Project Manager, at (240) 402 - 0997 or Pin.Zhang@fda.hhs.gov.

Sincerely,

Digitally signed by Matthew R. Holman -S Date: 2020.04.23 14:15:01 -04'00' Matthew R. Holman, Ph.D. Director Office of Science Center for Tobacco Products

Enclosures:

Appendix A – New and Corresponding Predicate Tobacco Products Subject of This Letter Appendix B – Health Information Summary

Appendix A

New and Corresponding Predicate Tobacco Products Subject of This Letter

Common Attributes of SE Reports		
Date of Submission:	September 5, 2019	
Product Manufacturer: Philip Morris USA Inc.		
Product Category: Cigarettes		
Product Sub-Category: Combusted, Filtered		
	New Tobacco Product	Predicate Tobacco Product
	SE0015426: Marlboro Red Label 100's	SE0014849: Marlboro Red Label 100's
	Box ³	Box ³
Package Type:	Hard Pack	Hard Pack
Package Quantity:	20 Cigarettes	20 Cigarettes
Characterizing Flavor:	None	None
Eligibility Status:	N/A	Previously Found SE
Length:	98.5 mm	98.5 mm
Diameter ⁴ :	7.89 mm	7.89 mm
Ventilation:	20%	20%
	New Tobacco Product	Predicate Tobacco Product
	SE0015427: Benson & Hedges 100's	GF1200121: Benson & Hedges 100's
	Box ³	Box ³
Package Type:	Hard Pack	Hard Pack
Package Quantity:	20 Cigarettes	20 Cigarettes
Characterizing Flavor:	None	None
Eligibility Status:	N/A	Grandfathered
Length:	98 mm	98 mm
Diameter ⁴ :	7.89 mm	7.89 mm
Ventilation:	26%	26%

³ Brand/sub-brand or other commercial name used in commercial distribution.

⁴ The applicant submitted the circumference which allowed for a calculation of diameter.

Appendix B

Health Information Summary

Your SE Reports did not provide a summary of any health information related to the new tobacco products, required by section 910(a)(4) of the FD&C Act; however, your SE Reports stated that such information will be available upon request to any person. Consistent with the requirements of section 910(a)(4), you may wish to consider providing the following when information is requested:

- A. A copy of your final SE Reports upon which the Substantially Equivalent order was based, redacted only to the extent necessary to exclude patient identifiers and trade secret and confidential commercial information as defined in 21 CFR 20.61 and 20.63.
- B. Any research or data you have in your possession or otherwise know of specifically regarding the adverse health effects of the new tobacco products, or the following statement if such statement is accurate: "[Insert manufacturer name] does not have or know of any research or data regarding any adverse health effects specifically related to [insert tobacco product name]."

Alternatively, you may provide the following when information is requested:

Description of the new tobacco products

Description of the predicate tobacco products

List of all differences in characteristics between the new and predicate tobacco products Summary of the evidence and scientific rationale concerning why the differences in characteristics do not raise different questions of public health

Any research or data you have in your possession or otherwise know of regarding the adverse health effects of the new tobacco product, or the following statement if such statement is accurate: "[Insert manufacturer name] does not have or know of any research or data regarding any adverse health effects specifically related to [insert tobacco product name]."

There may be other accurate, complete, and not false or misleading ways to satisfy the requirements of section 910(a)(4) not included above. If you wish to discuss other ways to meet the requirements of section 910(a)(4), submit a meeting request to us.